The text discusses the importance of RAS and BRAF V600E mutations in stage III colon cancer treatment, stating that adjuvant treatment with bevacizumab or cetuximab is not recommended. Starting adjuvant chemotherapy within 8 weeks of tumor resection is associated with a lower risk of death. Beyond 3 months post-surgery, the need for adjuvant chemotherapy should be carefully considered, with experts suggesting it may not be beneficial beyond 5 months.